Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study checks if immunotherapy works for advanced lung cancer patients

NCT ID NCT07279402

Disease control Sponsor: Antalya Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at how well the immunotherapy drug atezolizumab works as the first treatment for people with stage IV non-small cell lung cancer that has high PD-L1 levels (50% or more) and no targetable gene changes. Researchers will track 150 patients in Türkiye to see how long they live and how long the cancer stays under control during routine care. The goal is to understand if atezolizumab performs as well in everyday practice as it does in clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atezolizumab (an immunotherapy drug that helps the immune system fight cancer)
What this could lead to
If successful, this study could confirm that atezolizumab works well in everyday clinical practice for people with advanced lung cancer who have high PD-L1 levels.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also limited to patients in Türkiye, which may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with stage IV non-small cell lung cancer receiving first-line atezolizumab as part of routine clinical practice at participating oncology centers in Türkiye. The study population reflects real-world patients treated according to local standards of care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent form. * Diagnosis of stage IV non-small cell lung cancer. * Male or female patients aged 18 years or older. * Patients who have been prescribed atezolizumab in accordance with routine clinical practice and the locally approved indication in Türkiye. * Patients who have received up to 3 cycles of atezolizumab at the screening visit. Exclusion Criteria: * Patients who are not receiving atezolizumab for the treatment of lung cancer according to standard of care and the approved indication. * Known or suspected hypersensitivity to atezolizumab. * Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atezolizumab are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atezolizumab NSCLC stage IV PD-L1 gene mutation Real world study

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    25 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Adana City Hospital

    RECRUITING

    Adana, Turkey (Türkiye)

  • Adnan Menderes University Faculty of Medicine Hospital

    RECRUITING

    Aydin, 09100, Turkey (Türkiye)

  • Afyonkarahisar Health Sciences University Hospital

    RECRUITING

    Afyonkarahisar, 03100, Turkey (Türkiye)

  • Ankara Atatürk Sanatoryum Training and Research Hospital

    RECRUITING

    Ankara, Turkey (Türkiye)

  • Ankara Bilkent City Hospital

    NOT_YET_RECRUITING

    Ankara, 06800, Turkey (Türkiye)

  • Ankara Oncology Training and Research Hospital

    NOT_YET_RECRUITING

    Ankara, 06200, Turkey (Türkiye)

  • Antalya City Hospital

    RECRUITING

    Antalya, Turkey (Türkiye)

  • Antalya Training and Research Hospital

    RECRUITING

    Antalya, 07100, Turkey (Türkiye)

  • Bahçelievler Memorial Hospital

    NOT_YET_RECRUITING

    Istanbul, 34180, Turkey (Türkiye)

  • Başakşehir Çam and Sakura City Hospital

    RECRUITING

    Istanbul, Turkey (Türkiye)

  • Dicle University Hospital

    NOT_YET_RECRUITING

    Diyarbakır, 21280, Turkey (Türkiye)

  • Dokuz Eylul University Faculty of Medicine Hospital

    RECRUITING

    Izmir, 35340, Turkey (Türkiye)

  • Ege University Hospital

    RECRUITING

    Izmir, Turkey (Türkiye)

  • Gaziantep City Hospital

    RECRUITING

    Gaziantep, Turkey (Türkiye)

  • Karadeniz Technical University Farabi Hospital

    RECRUITING

    Trabzon, 61080, Turkey (Türkiye)

  • Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi

    NOT_YET_RECRUITING

    Istanbul, 34899, Turkey (Türkiye)

  • Medical Park Samsun Hospital

    NOT_YET_RECRUITING

    Samsun, 55080, Turkey (Türkiye)

  • Memorial Ankara Hospital

    NOT_YET_RECRUITING

    Ankara, 06560, Turkey (Türkiye)

  • Mersin University Faculty of Medicine Hospital

    RECRUITING

    Mersin, 33110, Turkey (Türkiye)

  • Necmettin Erbakan University Meram Faculty of Medicine Hospital

    RECRUITING

    Konya, 42080, Turkey (Türkiye)

  • Ordu State Hospital

    NOT_YET_RECRUITING

    Ordu, 52200, Turkey (Türkiye)

  • Sakarya University Faculty of Medicine Hospital

    RECRUITING

    Sakarya, 54050, Turkey (Türkiye)

  • Trakya University Faculty of Medicine Hospital

    RECRUITING

    Edirne, 22030, Turkey (Türkiye)

  • Ümraniye Training and Research Hospital

    NOT_YET_RECRUITING

    Istanbul, 34766, Turkey (Türkiye)

  • İstanbul Medipol Mega Hospital

    NOT_YET_RECRUITING

    Istanbul, 34214, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.